^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

PDC*mel

i
Other names: PDC*mel, GeniusVac-Mel4, dendritic cell-based cancer vaccine, GeniusVac Mel4, GeniusVacMel4
Associations
Trials
Company:
PDC line Pharma
Drug class:
Immunostimulant, gp100 inhibitor, MAGE-A3 inhibitor, Tyrosinase inhibitor, Melanoma cell surface antigen inhibitor
Related drugs:
Associations
Trials
almost4years
Generated SecPen_NY-ESO-1_ubiquitin-pulsed dendritic cell cancer vaccine elicits stronger and specific T cell immune responses. (PubMed, Acta Pharm Sin B)
Dendritic cell-based cancer vaccines (DC vaccines) have been proved efficient and safe in immunotherapy of various cancers, including melanoma, ovarian and prostate cancer...Given the above, it demonstrated that DC-SNU loaded with SecPen and ubiquitin-fused NY-ESO-1 could elicit stronger and specific T cell immune responses. This strategy can be used as a platform for DC vaccine preparation and applied to various cancers treatment.
Journal
|
IFNG (Interferon, gamma) • TNFA (Tumor Necrosis Factor-Alpha) • CTAG1B (Cancer/testis antigen 1B) • CD40 (CD40 Molecule)
|
PDC*mel
over4years
AN ANTICANCER DRUG COCKTAIL OF Three Kinase Inhibitors Improved Response to a DENDRITIC CELL-BASED CANCER VACCINE. (PubMed, Cancer Immunol Res)
We identified AKT inhibitor MK2206, DNA-PK inhibitor NU7441, and MEK inhibitor trametinib as the compounds most effective at modulating moDC immunogenicity...MKNUTRA treatment imparted to ICT107, a glioblastoma (GBM) DC-based vaccine that has completed phase II trials, an increased ability to stimulate patient-derived autologous CD8 T cells against the brain tumor antigens IL13Rα2 and TRP2In vivo, treating ICT107 with MKNUTRA, prior to injection into mice with an established GBM tumor, reduced tumor growth kinetics. This response was associated with an increased frequency of tumor-reactive lymphocytes within tumors and in peripheral tissues. These studies broaden the application of targeted anticancer drugs and highlight their ability to increase moDC immunogenicity.
Journal
|
CD8 (cluster of differentiation 8)
|
Mekinist (trametinib) • MK-2206 • NU7441 • ICT-107 • PDC*mel
over4years
Rapid tumor vaccine using Toll-like receptor-activated ovarian cancer ascites monocytes. (PubMed, J Immunother Cancer)
Ascites monocytes are naturally loaded with tumor antigen and can perform as potent APCs following short ex vivo activation. This novel ascites APC vaccine can be rapidly prepared in 48 hours with a straightforward and affordable manufacturing process, and would be an attractive therapeutic vaccine for OC.
Journal
|
HER-2 (Human epidermal growth factor receptor 2) • TP53 (Tumor protein P53) • MSLN (Mesothelin) • MUC1 (Mucin 1) • GPC3 (Glypican 3) • IL10 (Interleukin 10) • PRAME (Preferentially Expressed Antigen In Melanoma) • TLR4 (Toll Like Receptor 4)
|
PDC*mel